Genomed (GEN.WA) Stock Price

Genomed Price

CLOSED
37.40
​
Market closed

Over the last 9 years Genomed grew revenue by 10.1% annually, reaching 23.01 M PLN. Earnings per share have grown at 86.2% per year over the last 9 years. For Genomed, the net margin of 4.8% is up versus 2.2% a few years ago. At today's price the dividend yield works out to roughly 2.67%. The payout ratio is around 132% of earnings.

Genomed stock price

Access this data via the Eulerpool API

Genomed business model & stock analysis

Genomed SA engages in the provision of medical diagnostic services. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2011-05-30. The company develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Company’s offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Company’s activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The firm also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.

Frequently asked questions about Genomed

Converted at the current exchange rate, the Genomed share trades at 8.56 EUR (37.40 PLN).

The revenue cannot currently be calculated for Genomed.

The profit cannot currently be calculated for Genomed.

The P/E ratio cannot be calculated for Genomed at the moment.

The P/S cannot be calculated for Genomed currently.

The Eulerpool Quality Score for Genomed is 2/10.

The ISIN of Genomed is PLGNOMD00024. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Genomed is GEN.WA. The ticker symbol is used to trade Genomed shares on the stock exchange.

Fair ValueTerminal
35.53 PLN
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website genomed.pl
Country
Poland
Currency
PLN
Initial public offering
May 30, 2011
ISIN
PLGNOMD00024
Cusip
X30792109
Market capitalization
49.37 M PLNMicro Cap
52-Week Range
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
36.65
P/B Ratio
4.61
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
10.31 %
Gross Margin
63.00 %
EBIT Margin
5.23 %
Net Margin
4.80 %
EPS (Earnings Per Share)
0.84 PLN
Net Debt / EBIT
-4.35
Debt/Equity
0.00
Dividend
Dividend yield
0.00 %
Payout Ratio
131.89 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
0 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
19.00 %
Last updated Sep 30, 2026, 1:49 PM

Genomed Peer Group

Genomed FIGI

GEN:PW · BBG001P21SH4GENPLN:XS · BBG00PQ1ZGF3GENPLN:XH · BBG00PQ1ZGJ9GENPLN:XF · BBG00PQ1ZGL6GENPLN:XD · BBG00PQ1ZGM5GENPLN:XE · BBG00PQ1ZGN4GENPLN:XJ · BBG00PQ1ZGP2GENPLN:XL · BBG00PQ1ZGQ1GENPLN:XG · BBG00PQ1ZGR0GENPLN:XO · BBG00PQ1ZGS9GENPLN:XN · BBG00PQ1ZGT8GENPLN:XA · BBG00PQ1ZGX3

All fundamentals and in-depth analysis of Genomed

Our stock analysis for Genomed stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genomed. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.